Introduction
============

Gastric cancer (GC) ranks fourth in frequency in the world and is globally the second leading cause of cancer-related death [@B1], [@B2]. GC is the most common malignancy in Latin America and Asia, and its incidence is nearly 10-fold higher than in the US [@B3]. According to the 7th edition of the AJCC TNM classification, the minimum number of retrieved LNs is not defined [@B4]. Meanwhile, the number of metastatic LNs was validated as an independent prognostic factor after surgical resection [@B5], [@B6]. However, whether more retrieved LNs can be linked to accurate staging is controversial. In addition, there is doubt regarding the recommended minimum retrieval of 15 LNs for GC [@B7]. Some studies sought to investigate the optimal LNs retrieval cutoff in node-negative GC, but few studies have focused on node-positive patients in a large population [@B8].

The objective of this retrospective study was to assess the effect of retrieved LN counts on the long-term survival outcome in node-positive gastric patients, and to explore the optimal retrieved LNs cutoff value. In this study, we searched the Surveillance, Epidemiology, and End Results (SEER) population-based database and analyzed the clinicopathological characteristics and cancer-specific survival of these subgroups. We also used the X-tile program to determine the optimal cutoff.

Methods
=======

Patient selection
-----------------

Data were obtained from the Surveillance Epidemiology and End Results (SEER) Program of the United States National Cancer Institute. The current SEER database consists of 18 population-based cancer registries that represent approximately 26% of the population in the United States. SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis.

Inclusion criteria included the following: (1) patients were diagnosed from 2004 to 2012; (2) the site code was limited to stomach; (3) underwent surgical resection; (4) age \> 18 years old; (5) histology code was limited to adenocarcinoma (8140/3, 8144/3, 8255/3, 8211/3, 8260/3,8263/3), mucinous adenocarcinoma (8480/3), and signet ring cell carcinoma (8490/3); (6) at least with one LN retrieval; (7) information on CSS and OS available. The primary endpoint of the study is 5-year CSS, which was calculated from the date of diagnosis to the date of cancer-specific death. Cancer-specific deaths were treated as events, and deaths from other causes were treated as censored observations. The median follow-up of patients was calculated from the date of diagnosis to the date of cancer-specific death.

This study was based on public data from the SEER database; we obtained permission to access research data files with the reference number 10504-Nov2014. The data did not include the use of human subjects or personal identifying information. Thus, no informed consent was required for this part of the study. The methods were carried out in accordance with the approved guidelines in this study. Ethical approval was obtained from the institutional review board of Nanjing Medical University.

Identification of the optimal cutoff point of retrieved LNs
-----------------------------------------------------------

The retrieved LNs cutoff points were produced and analyzed using the X-tile program, which identified the cutoff with the minimum p values from log-rank χ2 statistics for the categorical LN counts in terms of survival.

Statistical analysis
--------------------

Categorical variables were summarized using frequency (%). A comparison of the categorical variables between LNs count subgroups was conducted using Pearson\'s χ2 test. Continuous variables were compared using the Mann-Whitney U test. Survival curves were generated using the Kaplan-Meier method; differences between the curves were analyzed by the log-rank test. Multivariable Cox proportional hazards regression models were used to assess potential risk factors for CSS. Cox stepwise regression analysis was also performed to determine predictive factors for gastric cancer prognosis, with a significance level of 0.05 for entering and 0.10 for removing the respective explanatory variables. Nomograms for possible prognostic factors associated with CSS and OS were established by R software, and the model performance for predicting outcome was evaluated by Harrell\'s concordance index (c-index), which is a measure of discrimination.

All statistical analyses were performed using the statistical software package SPSS for Windows, version 17 (SPSS Inc., Chicago, IL, USA). The results were considered statistically significant when a two-tailed test provided a P-value of less than 0.05.

Results
=======

Patient Characteristics
-----------------------

We identified 8475 eligible patients with GC meeting the eligibility criteria in the SEER database, including 5404 male and 3071 female. All patients had at least one LN examined. There were 2738 patients with N1 stage, 2493 patients with N2 stage, 2252 patients with N3a stage, and 992 patients with N3b stage. Patient demographics and pathological features are summarized in Table [1](#T1){ref-type="table"}. Patients had a higher rate of poor/ anaplastic grade tumors, a higher ratio of cardia and gastric antrum tumors, a higher proportion of adenocarcinoma and T3/4 tumor stage across all the N (+) patients (P\< 0.001). The median number of LNs examined was 17.89 (range, 9-23). The median positive LN count was 7.19 (range, 2-10).

Identification of minimum number of retrieved LNs in node-positive patients
---------------------------------------------------------------------------

X-tile plots were constructed and the maximum of chi-square log-rank values of 154.244 (P\< 0.001) was achieved when applying 6 and 14 as the cutoff value of retrieved LNs. This value can be used to divide the cohort into high, middle and low risk subsets in terms of gastric cancer-specific survival (GCSS), which were 20.3%, 29.0% and 32.6%, respectively (P\< 0.001) (Fig. [1](#F1){ref-type="fig"}). Then, to investigate the impact of different LN counts on GCSS, we treated the number of LN counts as a continuous variable and analyzed the number of retrieved LNs from 2 to 20. The number of retrieved LNs was an independent prognosis factor for GC, and patients with 15 or more LNs retrieved had a relative14.4% improvement in 5-year GCSS compared to those with 6 less LNs retrieved (32.6% versus 18.2%). The 5-year GCSS of patients with N or more nodes increased gradually when N reaching 14. After the number 15, the survival rates were roughly stable between the compared groups (Table [2](#T2){ref-type="table"}).

Effect of LN counts on GCSS rates in the SEER database
------------------------------------------------------

The univariate log-rank test showed that, beside of the number of retrieved LNs, other clinicopathological factors, including age more than 60 years, White race, poor/undifferentiated tumor grade, overlapping lesion of stomach, mucinous and signet-ring cancer as well as advanced TN stages were regarded as significant risk factors for 5-year CSS rate (P\< 0.001). Multivariate analysis with Cox regression demonstrated that more retrieved LNs exhibited survival advantage (LNs: 7-14, hazard ratio (HR) 0.586; 95% confidence interval \[CI\] 0.536-0.640; LNs: ≥15, HR 0.390; 95% CI 0.356-0.427) (P\< 0.001) (Table [3](#T3){ref-type="table"}).

Prognostic nomogram for CSS and OS
----------------------------------

To predict CSS and OS in GC patients, the external validation of nomograms was performed and predictive factors were determined by cox stepwise regression analysis (Fig. [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B) [@B9]. Each variable was assigned a score at the top of scale. By counting the total score, we were able to draw a straight line down to predict 3-year and 5-year probability of survival for a patient at each time point. The Harrell\'s c-indexes to predict CSS and OS prediction were 0.663 (95% CI: 0.655-0.671) and 0.654 (95% CI: 0.646-0.662) (P\< 0.001), which were significantly higher than those of the model without the variable of dissected LNs (CSS: 0.663 versus 0.64; OS: 0.654 versus 0.63) (P\< 0.001). Calibration curves for two nomograms (Fig. [3](#F3){ref-type="fig"}C and [3](#F3){ref-type="fig"}D) revealed no deviations from the reference line and no need of recalibration. The decision curve analysis indicated that for most of the threshold probabilities for 5-year CSS and OS, with LN count nomogram achieved a greater net benefit compared with without LN count (Fig. [S1](#SM0){ref-type="supplementary-material"}).

Subgroup analysis of retrieved LNs effect on GCSS according to pN categories
----------------------------------------------------------------------------

We then further analyzed the effect of retrieved LNs on GCSS rates in each stage. After stratifying by the confounding factors, the univariate analysis of retrieved LNs effect on GCSS rates showed that the retrieved LNs exhibited increased 5-year GCSS rates across several N subgroups (P\< 0.001). Comparing with the patients who had ≤6 retrieved LNs, there was a 35.0% and 27.1% improvement in 5-year GCSS in those ≥15 retrieved LNs patients in N1 and N2 stage, and stills a 7.5% improvement when compared with 7-14 retrieved LNs patients in N3 stage (P\< 0.001). Besides, the retrieved LNs were also validated as an independent predictor of survival in multivariate Cox regression in N1 stage (LNs≥15, HR 0.373, 95% CI 0.325-0.427, P\< 0.001), N2 stage (LNs≥15, HR 0.406, 95% CI 0.352-0.469, P\< 0.001) and N3 stage (LNs≥15, HR 0.789, 95% CI 0.719-0.865, P\< 0.001) (Table [4](#T4){ref-type="table"}).

Discussion
==========

Although the increased trend in the diagnosis of GC, the prognosis of GC is still poor and the 5-year survival was less than 30% [@B10]. Radical gastrectomy is considered as the only potentially curative therapy for all the GC patients [@B11]. LN metastases in gastric cancer are well recognized as one of the most important prognostic factors, and regional lymph nodes dissection could improve the long-term survival [@B12], [@B13]. The American Joint Committee on Cancer (AJCC) has recommended a minimum of 15 lymph nodes should be examined in order to get accurate postoperative stage [@B14], [@B15]. According to the 8th edition TNM classification, the minimum examined lymph node count is not mandatory for proper staging, although more than 16 examined LNs has been proposed to ensure the accurate prognosis of pN stage since 2009[@B16]. Moreover, the number of retrieved LNs has been confirmed as an independent prognosis factor in esophageal cancer [@B17], colon cancer [@B18] et al. However, debate also exists regarding the importance and the number of retrieved LNs in gastric cancer. Okajima et al. suggested that 25 or more LN harvests might be sufficient for nodal staging [@B19]. Liu et al. recommended no less than 15 total LNs should be pathologically examined in patients with N1-3 [@B20]. Shi et al. also reported that negative lymph node counts, which did not take positive LN into consideration, could predict prognosis for patients with gastric cancer [@B5]. In addition, in node-negative gastric cancer, Zheng et al. found retrieved LN counts was associated with long-time survival outcomes. The higher the LN count, the better the survival would be [@B8]. Deng et al. found that more than 15 examined LNs in node-negative GC patients were mandatory for improvement in the prognostic assessment accuracy [@B21]-[@B23]. However, the relationship between total LN counts and GCSS has not been fully investigated in a large population.

According to all present clinical guidelines, total LN counts for gastric cancer are the main concern. In view of the importance of total LN counts, in this study, we mainly investigate the prognostic value of total LN counts in node-positive GC. We first used the X-tile program to divided GC patients into low, middle, and high-risk groups, and identified 4 and 14 as the optimal cutoff value in terms of GCSS. Then the result was further confirmed in an additional one-by-one cutoff value analysis from 2 to 20. The 5-year GCSS of patients with N or more nodes increased gradually when N reached 14. After the number 15, the survival rates were roughly stable between the compared groups. Above results indicated that inadequate LN harvest in node-positive gastric cancer patients may reflect limited lymph node dissection for gastric cancer, which increased the risk of recurrence and metastasis. Besides, we also validated retrieved LN counts as an independent prognostic factor in node-positive gastric cancer. The survival rates were positively correlated with the number of retrieved LN counts.

The nomogram is a simple statistics-based tool that provides the overall probability of a specific clinical event. For many cancers, nomograms are validated to be more accurate in predicting the probability of an event, such as death or recurrence, when compared with the traditional TNM staging systems [@B24]. The X-tile software is a comprehensive method, based on traditional statistical tests, and yet intuitive for the oncologist. The X-tile plot illustrates the presence of substantial subpopulations and shows the robustness of the relationship between a biomarker and outcome by construction of a two dimensional projection of every possible sub-population [@B25]. In this study, we used nomograms incorporating different retrieved LN number that identified the optimal cut-off value by X-tile program in a large population, and exhibited better predictive accuracy than that of the model without the variable of dissected LNs.

Several hypotheses may explain this finding for the relationship between the number of retrieved LNs and survival. First, total LN counts indicate the actual harvested LNs number intraoperatively. Moreover, it also reflects the properly identified and examined LNs during pathologic analysis of the surgical specimen, which result in cancer upstaging. Second, previous studies have shown that patients with lymphocytic infiltration have a better survival than those who have no infiltration [@B26], [@B27]. More dissected LNs which are associated with LN counts may reflect a higher host lymphocytic reaction to the tumor [@B28], [@B29]. Furthermore, we have to remain aware of the fact that increased number of retrieved LNs may attribute to improved surgical techniques. Theoretically, it also reflects an authoritative surgical curability and quality of surgical care or pathology, thus prolonging the survival and disease-free period.

Although this study is based on a large population, there are still potential limitations. First, several important pieces of information regarding surgical options (eg, palliative therapy, radical resection), as well as cancer treatment (chemotherapy, radiotherapy), are not included in the SEER database, which could not be adjusted by our analyses. Second, SEER database also lacks the situation of postoperative adjuvant chemotherapy, and information about the depth of tumor invasion (T4a/T4b), as well as the information of pathology-specific covariates including perineural invasion and vascular invasion which are essential for prognosis evaluation. Third, the number of lymph nodes harvested depends on the quality of surgery and pathology. These variables that cannot be adjusted may differ in different institutions. Despite these limitations, our analysis of the SEER database revealed that total LN counts were an independent prognostic predictor with surgically treated gastric cancer. Increased retrieved LNs count was associated with long-time survival outcomes in node-positive gastric cancer; it could provide more accurate prognostic information than the current node stage system.
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![**X-tile analysis of survival data from the SEER registry.** X-tile analysis was done on patient data from the SEER registry, equally divided into training and validation sets. The optimal cut-point highlighted by the black circle in the left panels (A) is shown on a histogram of the entire cohort (middle panels) (B), and a Kaplan-Meier plot (right panels) (C). P values were determined by using the cut-point defined in the training set and applying it to the validation set. Figure [1](#F1){ref-type="fig"} shows the optimal cutoff point for the lymph node positive patients (number 6 and 14, χ2=154.244, P \< 0.001).](jcav10p5646g001){#F1}

![**Log-rank tests of cause specific comparing those who had ≥15, 7-14, and ≤6 positive lymph nodes for** A. all stage: χ2 = 491.935, P \< 0.001; B. N1 stage: χ2 = 305.678, P \< 0.001; C. N2 stage: χ2 = 200.635, P \< 0.001; D. N3 stage: χ2 = 29.113, P \< 0.001.](jcav10p5646g002){#F2}

![**The calibration plots for predicting CSS and OS of gastric cancer patients.** Nomograms can be interpreted by summing up the points assigned to each variable, which is indicated at the top of scale. The total points can be converted to predicted 3-year and 5-year probability of survival for a patient in the lowest scale (A, B). The Harrell\'s c-indexes for CSS and OS prediction were 0.663 (95% CI: 0.655-0.671) and 0.654 (95% CI: 0.646-0.662) (P\< 0.001), respectively. Calibration curves for 5-year CSS (C) and 5-year OS (D) using nomograms with clinicopathological characteristics and LN counts are shown. The x-axis is nomogram-predicted probability of survival and y-axis is actual survival. The reference line is 45°and indicates perfect calibration.](jcav10p5646g003){#F3}

###### 

Demographic and tumor characteristics of patients with node positive gastric cancer

                                                   Subgroup      P value                                                                          
  ---------------------------------- ------------- ------------- ------------- -------------- -------------- --------- ------ ------ ----- ------ ---------
  **Sex**                                                                                                                                         0.016
  male                               5404          63.8          1775          64.8           1613           64.7      1426   63.3   590   59.5   
  female                             3071          36.2          963           35.2           880            35.3      826    36.7   402   40.5   
  **Age**                                                                                                                                         \<0.001
  \<60                               2924          34.5          846           30.9           843            33.8      876    38.9   359   36.2   
  ≥60                                5551          65.5          1892          69.1           1650           66.2      1376   61.1   633   63.8   
  **Race**                                                                                                                                        \<0.001
  White                              5629          66.4          1856          67.8           1681           67.4      1453   64.5   639   64.4   
  African American                   1170          13.8          381           13.9           364            14.6      301    13.4   124   12.5   
  Others                             1676          19.8          501           18.3           448            18.0      498    22.1   229   23.1   
  **Location**                                                                                                                                    \<0.001
  Cardia, NOS                        2198          15.9          864           31.6           711            28.5      474    21.0   149   15.0   
  Fundus of stomach                  255           3.0           76            2.8            92             3.7       56     2.5    31    3.1    
  Body of stomach                    661           8.0           202           7.4            185            7.4       180    8.0    94    9.5    
  Gastric antrum                     2118          25.0          652           23.8           631            25.3      596    26.5   239   24.1   
  Pylorus                            403           4.8           130           4.7            129            5.2       117    5.2    27    2.7    
  Lesser curvature of stomach NOS    952           11.2          295           10.8           248            9.9       286    12.7   123   12.4   
  Greater curvature of stomach NOS   402           4.7           128           4.7            108            4.3       111    4.9    55    5.5    
  Overlapping lesion of stomach      756           8.9           174           6.4            182            7.3       245    10.9   155   15.6   
  Stomach, NOS                       730           8.6           217           7.9            207            8.3       187    8.3    119   12.0   
  **Pathological grading**                                                                                                                        \<0.001
  High/ Moderate                     1985          23.4          853           31.2           611            24.5      404    17.9   117   11.8   
  Poor/ Anaplastic                   6171          72.8          1731          63.2           1813           72.7      1782   79.1   845   85.2   
  Unknown                            319           3.8           154           5.6            69             2.8       66     2.9    30    3.0    
  **Histotype**                                                                                                                                   \<0.001
  Adenocarcinoma                     5962          70.3          2110          77.1           1825           73.2      1474   65.5   553   55.7   
  Mucinous /Signet ring cell         2513          29.7          628           22.9           668            26.8      778    34.5   439   44.3   
  **pT stage**                                                                                                                                    \<0.001
  T1                                 581           6.9           373           13.6           159            6.4       41     1.8    8     0.8    
  T2                                 786           9.3           412           15.0           227            9.1       122    5.4    25    2.5    
  T3                                 3596          42.4          1090          39.8           1169           46.9      1007   44.7   330   33.3   
  T4                                 3460          40.8          820           29.9           934            37.5      1078   47.9   628   63.3   
  Tx                                 52            0.6           43            1.6            4              0.2       4      0.2    1     0.1    
  **No. of LNs dissected**           17.89(9-23)   13.18(5-18)   15.91(8-20)   19.67(13-24)   31.87(22-38)   \<0.001                              
  No. of positive LNs                7.19(2-10)    1.40(1-2)     4.26(3-5)     10.14(8-12)    23.80(18-27)   \<0.001                              

###### 

Univariate analysis for the influence of different cutoffs on GCSS in gastric cancer.

  Cutoff   No.    5-year GCCS   Log-rank χ^2^   P value
  -------- ------ ------------- --------------- ---------
  \<2      268    10.2%         125.990         \<0.001
  ≥2       8207   30.3%                         
  \<3      413    13.3%         114.568         \<0.001
  ≥3       8062   30.5%                         
  \<4      591    15.2%         130.281         \<0.001
  ≥4       7884   30.7%                         
  \<5      787    18.7%         99.070          \<0.001
  ≥5       7688   30.8%                         
  \<6      998    18.2%         132.053         \<0.001
  ≥6       7477   31.2%                         
  \<7      1252   20.3%         118.442         \<0.001
  ≥7       7223   31.3%                         
  \<8      1544   21.7%         114.520         \<0.001
  ≥8       6931   31.4%                         
  \<9      1808   22.1%         121.692         \<0.001
  ≥9       6667   31.7%                         
  \<10     2165   23.0%         117.830         \<0.001
  ≥10      6310   31.9%                         
  \<11     2521   24.7%         83.525          \<0.001
  ≥11      5954   31.7%                         
  \<12     2883   24.8%         88.381          \<0.001
  ≥12      5592   32.2%                         
  \<13     3234   25.6%         77.568          \<0.001
  ≥13      5241   32.2%                         
  \<14     3587   25.8%         77.682          \<0.001
  ≥14      4888   32.5%                         
  \<15     3882   26.2%         70.925          \<0.001
  ≥15      4593   32.6%                         
  \<16     4239   26.6%         60.232          \<0.001
  ≥16      4236   32.7%                         
  \<17     4557   26.9%         53.464          \<0.001
  ≥17      3918   32.9%                         
  \<18     4873   26.8%         59.287          \<0.001
  ≥18      3602   33.5%                         
  \<19     5178   27.7%         42.607          \<0.001
  ≥19      3297   32.8%                         
  \<20     5431   28.0%         38.271          \<0.001
  ≥20      3044   32.7%                         

###### 

Univariate and multivariate survival analyses for evaluating the influence of the number of retrieved LNs influencing GCSS in node positive gastric cancer patients.

                                             Univariate analysis   Multivariate analysis                        
  ---------------------------------- ------- --------------------- ----------------------- -------------------- ---------
  Sex                                        3.059                 0.08                                         
  Male                               30.4%                                                                      
  Female                             28.5%                                                                      
  Age                                        23.923                \<0.001                                      \<0.001
  \<60                               32.0%                                                 Reference            
  ≥60                                28.4%                                                 1.295(1.221-1.373)   
  Race                                       51.463                \<0.001                                      \<0.001
  White                              27.6%                                                 Reference            
  African American                   28.2%                                                 1.042(0.960-1.131)   
  Others                             37.5%                                                 0.809(0.751-0.871)   
  **Location**                               72.114                \<0.001                                      0.0251
  Cardia, NOS                        26.1%                                                 Reference            
  Fundus of stomach                  31.4%                                                 0.827(0.700-0.978)   
  Body of stomach                    30.5%                                                 0.769(0.687-0.861)   
  Gastric antrum                     32.6%                                                 0.778(0.718-0.842)   
  Pylorus                            29.7%                                                 0.857(0.748-0.982)   
  Lesser curvature of stomach NOS    37.1%                                                 0.693(0.625-0.768)   
  Greater curvature of stomach NOS   31.2%                                                 0.812(0.707-0.931)   
  Overlapping lesion of stomach      23.3%                                                 0.860(0.774-0.955)   
  Stomach, NOS                       26.6%                                                 0.891(0.801-0.992)   
  **Pathological grading**                   98.930                \<0.001                                      \<0.001
  High/ Moderate                     37.9%                                                 Reference            
  Poor/ Anaplastic                   27.4%                                                 1.156(1.077-1.241)   
  Unknown                            21.7%                                                 1.186(1.021-1.377)   
  Histotype                                  45.168                \<0.001                                      0.060
  Adenocarcinoma                     32.1%                                                 Reference            
  Mucinous/signet ring cell          24.0%                                                 1.061(0.998-1.129)   
  pT Stage                                   731.610               \<0.001                                      \<0.001
  T1                                 60.2%                                                 Reference            
  T2                                 51.1%                                                 1.156(0.969-1.380)   
  T3                                 31.7%                                                 1.835(1.584-2.126)   
  T4                                 17.9%                                                 2.604(2.246-3.019)   
  Tx                                 4.2%                                                  4.453(3.216-6.164)   
  pN Stage                                   620.680               \<0.001                                      \<0.001
  N1                                 42.9%                                                 Reference            
  N2                                 32.2%                                                 1.371(1.270-1.480)   
  N3a                                19.7%                                                 2.186(2.010-2.378)   
  N3b                                9.2%                                                  3.524(3.169-2.919)   
  No. of LNs                                 135.822               \<0.001                                      \<0.001
  ≤6                                 20.3%                                                 Reference            
  7-14                               29.0%                                                 0.586(0.536-0.640)   
  ≥15                                32.6%                                                 0.390(0.356-0.427)   

NI: not included in the multivariate survival analysis.

P values were adjusted for age, race, location, pathological grading, histotype stage, tumor stage and No. of LNs as covariates.

###### 

Univariate and multivariate survival analyses evaluating the number of retrieved LNs influencing GCSS based on different cancer stage.

                         Univariate analysis   Multivariate analysis                        
  -------------- ------- --------------------- ----------------------- -------------------- ---------
  **pN Stage**                                                                              
  **N1**                 305.678               \<0.001                                      \<0.001
  No. of LNs                                                                                
  ≤6             23.1%                                                 Reference            
  7-14           44.3%                                                 0.581(0.511-0.661)   
  ≥15            58.1%                                                 0.373(0.325-0.427)   
  **N2**                 200.635               \<0.001                                      \<0.001
  No. of LNs                                                                                
  ≤6             13.6%                                                 Reference            
  7-14           29.2%                                                 0.582(0.507-0.669)   
  ≥15            40.7%                                                 0.406(0.352-0.469)   
  **N3**                 29.113                \<0.001                                      \<0.001
  No. of LNs                                                                                
  ≤6                                                                                        
  7-14           10.8%                                                 Reference            
  ≥15            18.3%                                                 0.789(0.719-0.865)   

P values were adjusted for age, race, location, pathological grading, histotype stage and tumor stage as covariates.

NI: not included in the multivariate survival analysis.
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